Synthetic Biology’s Major Pain Point: Scale

Mar 13, 2022

11:30am – 12:30pm CT

Recording: Synthetic Biology’s Major Pain Point: Scale, Mar 13, 2022

While there are numerous SynBio startups that have reached unicorn status, many of them haven’t produced a single molecule. Those that have a product can’t successfully scale. In this panel, industry experts break down how both SynBio companies and investors can address this issue to effectively bring new solutions to the market.

Programming descriptions are generated by participants and do not necessarily reflect the opinions of SXSW.

Deepak Dugar

Visolis, Inc.

Julianna LeMieux

Genetic Engineering & Biotechnology News

Kallie Li

Debut Biotechnology

Kulika Weizman

Creative Ventures

Primary Entry
Music Badge
Platinum Badge
Film Badge
Interactive Badge